Mecapegfilgrastim
Also known as: AGEN-1, Jinhao, mecapegfilgrastim, PEG-rhG-CSF, Pegfilgrastim biosimilar, 津优力
Source Mecapegfilgrastim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Mecapegfilgrastim is a pegylated form of filgrastim used to reduce the duration of chemotherapy‑induced neutropenia and the associated risk of infection.
Mechanism of Action
Binds G‑CSF receptor on myeloid progenitors, stimulating proliferation, differentiation and activation of neutrophils
Routes of Administration
Goals & Uses
- Mobilization of peripheral blood progenitor cellsStem Cell TransplantationLow
- Support for stem cell mobilizationHematologyModerate
- Chemotherapy‑induced neutropenia prophylaxisOncologyHigh
- Reduction of duration of severe neutropeniaHematologic SupportHigh
- Prevention of chemotherapy-induced febrile neutropeniaHematologic Support / Oncology Supportive CareHigh
Contraindications
- Hypersensitivity to G‑CSF or PEGAllergyHigh
- Myeloid malignancies (AML, CML, MDS)OncologicHigh
- Use within 14 days before or 24 hours after cytotoxic chemotherapyTiming RestrictionHigh
- Hypersensitivity to filgrastim, pegfilgrastim, or E. coli-derived proteinsAllergy / ImmunologicHigh
- Sickle cell diseaseHematologyModerate
Adverse Effects
- Acute respiratory distress syndrome (ARDS)PulmonaryRare
- Splenomegaly / splenic ruptureOrgan ToxicityRare
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- LeukocytosisHematologicUncommon
- Hypersensitivity reactionImmunologicUncommon
- Splenic ruptureGastrointestinal/HematologicRare
- Allergic/hypersensitivity reactionsImmunologicalUncommon
- Bone pain / musculoskeletal painMusculoskeletalCommon
Drug Interactions
- Cytotoxic chemotherapy agentsHigh
- Concurrent myeloid growth factorsModerate
- Cytotoxic chemotherapyLow
- LithiumLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Sickle cell diseaseHematologicRelative
- Pregnant womenReproductiveRelative
- Pediatric patients <2 yearsAgeAbsolute
Regulatory Status
- European UnionApprovedApproved: prevention of chemotherapy‑induced neutropeniaEMA‑approved biosimilar of pegfilgrastim
- United StatesInvestigationalNot yet FDA‑approved as of 2026
- United KingdomUnapprovedNot approved by MHRA as of knowledge cutoff; approved and marketed in China by CSPC Pharmaceutical
Approved by China's National Medical Products Administration (NMPA) for reduction of chemotherapy-induced neutropenia. Not approved by US FDA or EMA as of knowledge cutoff.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Mecapegfilgrastim?
Mecapegfilgrastim is a pegylated form of filgrastim used to reduce the duration of chemotherapy‑induced neutropenia and the associated risk of infection.
What is Mecapegfilgrastim used for?
Mecapegfilgrastim is educationally associated with: Mobilization of peripheral blood progenitor cells, Support for stem cell mobilization, Chemotherapy‑induced neutropenia prophylaxis, Reduction of duration of severe neutropenia, Prevention of chemotherapy-induced febrile neutropenia. Educational only — not medical advice.
How is Mecapegfilgrastim administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Mecapegfilgrastim?
Reported adverse effects include: Acute respiratory distress syndrome (ARDS), Splenomegaly / splenic rupture, Bone pain, Injection site reactions, Leukocytosis, Hypersensitivity reaction, Splenic rupture, Allergic/hypersensitivity reactions, Bone pain / musculoskeletal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Mecapegfilgrastim?
Recorded contraindications: Hypersensitivity to G‑CSF or PEG, Myeloid malignancies (AML, CML, MDS), Use within 14 days before or 24 hours after cytotoxic chemotherapy, Hypersensitivity to filgrastim, pegfilgrastim, or E. coli-derived proteins, Sickle cell disease. Consult a qualified clinician before use.